Question · Q4 2025
Brittany Socha asked about physician feedback on the three-year FIREFLY data, how much of Q4 2025 OJEMDA sales growth was attributable to this data, and when the bulk of its impact on sales figures is expected.
Answer
CCO Lauren Merendino reported very positive physician responses to the three-year FIREFLY-1 data, especially regarding time to next treatment. She stated that the impact on Q4 2025 performance was minimal, as awareness was primarily within the KOL community. The bulk of the impact is expected in 2026, following broader education and a peer-reviewed publication, which will enable active promotion.
Ask follow-up questions
Fintool can predict
DAWN's earnings beat/miss a week before the call